Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending June 30, 2023 was 2.68 (a -41.84% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA decreased by -48.55%
- Annual Net Debt/EBITDA for 2022 was 1.34 (a -42.88% decrease from previous year)
- Annual Net Debt/EBITDA for 2021 was 2.35 (a -60.62% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was 5.97 (a 452.76% increase from previous year)
Visit stockrow.com/DYN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of Dyne Therapeutics, Inc.
Most recent Net Debt/EBITDAof DYN including historical data for past 10 years.Interactive Chart of Net Debt/EBITDA of Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | 2.68 | 4.61 | – | – | – |
| 2022 | 5.68 | 5.21 | 4.99 | 8.36 | 1.34 |
| 2021 | 6.76 | 8.93 | 14.87 | 19.77 | 2.35 |
| 2020 | 12.2 | 27.67 | 0.0 | 0.0 | 5.97 |
| 2019 | – | – | 0.0 | 0.0 | 1.08 |
| 2018 | – | – | – | – | 1.0 |
Business Profile of Dyne Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology